High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer
1997

High serum levels of soluble CD44 variant isoform v5 and ovarian cancer outcomes

Sample size: 96 publication Evidence: moderate

Author Information

Author(s): AG Zeimet, M Widschwendter, M Uhl-Steidi, E Muller-Holzner, G Daxenbichier, C Marth, 0 Dapunt

Primary Institution: University Hospital, Innsbruck, Austria

Hypothesis

High pretreatment serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcomes in ovarian cancer patients.

Conclusion

The study found that high levels of soluble CD44 variant isoform v5 in serum are linked to better survival rates in ovarian cancer patients.

Supporting Evidence

  • Patients with CD44v5 levels above 35 ng/ml had a significantly better survival rate.
  • High CD44v5 levels were inversely correlated with indicators of immune system activation.
  • Lower CD44v5 levels were associated with higher CA-125 levels, a tumor marker.

Takeaway

If a patient with ovarian cancer has high levels of a specific protein called CD44v5 in their blood, they are more likely to do well.

Methodology

The study measured serum levels of soluble CD44 isoforms in ovarian cancer patients and compared them with healthy controls, using enzyme-linked immunosorbent assays.

Limitations

The study was retrospective and excluded patients with immune system disorders or previous cancer treatments.

Participant Demographics

Patients aged 23-88 years, median age 64, with advanced epithelial ovarian cancer.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication